Meet with our clients in San Francisco! #JPM2025
此处无法显示此内容
在领英 APP 中访问此内容等
关于我们
Precision AQ - Investor Relations & External Communications is a premier investor relations firm, representing biotechnology companies across all market capitalizations and stages of development, and offering strategic and client-specific advisory services. For more information please visit our website at www.precisionaq.com
- 网站
-
https://www.sternir.com
Precision AQ - Investor Relations & External Communications的外部链接
- 所属行业
- 公共关系和沟通服务
- 规模
- 11-50 人
- 总部
- New York
- 类型
- 私人持股
- 领域
- Investor Relations、Healthcare, Pharmaceuticals and Biotechnology和External Communications
地点
-
主要
获取路线
1270 Avenue of the Americas
US，New York，10020
Precision AQ - Investor Relations & External Communications员工
动态
-
Precision AQ - Investor Relations & External Communications转发了
Did you know gratitude benefits for your overall wellbeing? It strengthens our feelings of connection, alleviates depression, and increases our sense of engagement with the world around us. As we reflect on what we are thankful for, we wish our friends, family, and colleagues a holiday season brimming with gratitude. We especially want to express our appreciation to our employees and clients for their boundless enthusiasm and tireless commitment to advancing the medical treatments that improve the quality of life for patients in need.
-
-
We are very excited that our own Stephanie Ascher will be joining other industry experts tomorrow for a webinar about mastering AI in IR! Thanks for having us IR Magazine and Q4. Register and join us tomorrow using the following link: https://lnkd.in/e62x8prK
We're thrilled to have leading experts joining us on tomorrow's webinar all about mastering AI in IR while keeping your data safe and secure! We'll be hearing from: ?? Mark Hayes, partner and head of capital markets at Breakwater Strategy ?? Simone P., principal product manager at Q4 ?? Stephanie Ascher, managing director and team lead at Precision AQ ?? Moderator: Laurie Havelock, editor of IR Magazine It's free to attend and will get you up to speed in just 45 minutes. Register online at https://lnkd.in/e62x8prK In partnership with Q4
-
-
Precision AQ - Investor Relations & External Communications转发了
Be part of a group that has supported a growing number of “firsts” in breakthrough treatments for patients. Precision AQ is part of {{linkedin_mention(urn:li:organization:10619522|Precision Medicine Group)}} along with {{linkedin_mention(urn:li:organization:3077719|Precision For Medicine)}}. Together our expertise and capabilities span the continuum of pre-clinical and clinical development through commercialization. A few of the “firsts” we’ve supported on behalf of our clients include: 1st PD-1 inhibitor approved to treat cancer 1st CAR-T cell therapy ever approved by the FDA 1st CRISPR-based genome editing therapy ever approved by the FDA 1st ever commercial gene therapy for children with SMA And many more… See our story in the new video and consider joining us! We are hiring around the world. Find your position at https://lnkd.in/er6dWy3W
See our story in the new video and consider joining us! We are hiring around the world.
-
Congratulations to client LENZ Therapeutics on the announcement of their FDA NDA acceptance. The FDA has set their PDUFA date for August 2025!
{{linkedin_mention(urn:li:organization:78005945|LENZ Therapeutics)}} Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia. FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025 “With the acceptance of our New Drug Application for LNZ100, we are pleased to be one step closer towards potential approval and look forward to continuing to collaborate with the FDA to deliver the first once-daily, well-tolerated and rapid acting eye drop for the treatment of presbyopia to the 128 million individuals living with blurry near vision in the United States,” said {{linkedin_mention(urn:li:person:T3JA8UK24G|Eef Schimmelpennink)}}, President and Chief Executive Officer of LENZ Therapeutics. “Since our public debut in March 2024, we have generated tremendous momentum and demonstrated consistent clinical, regulatory and financial execution, and are focused on transforming LENZ into a robust commercial organization in anticipation of a potential launch as early as the second half of 2025.” Read full press release here: https://lnkd.in/gKz5jKfy
-
-
Congratulations to client Avadel Pharmaceuticals PLC?on the announcement of FDA approval of #LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with #narcolepsy!
We’re pleased to announce an important milestone for the #narcolepsy community, specifically for pediatric patients and their caregivers.? ? Learn more about another positive step in our efforts to transform the lives of people with narcolepsy.? https://lnkd.in/gFm6kxvx
-
-
? Last chance! ? We have a few spots left to join our virtual event TODAY at 12pm ET. Discover how Precision AQ can simplify your experience around #JPMorgan2025! Click here to register: https://lnkd.in/dSUQgrBP
-
-
Join our virtual event this Thursday, October 17th at 12pm ET to discover how Precision AQ can simplify your experience around #JPMorgan2025. This is your opportunity to partner with a team that makes your conference experience effortless and empowers you to focus on driving your life-changing innovations forward. Click here to register: https://lnkd.in/dSUQgrBP
-
-
The JP Morgan Healthcare Conference transforms San Francisco into the epicenter of #biotech: every year, industry giants unveil big news and early-stage companies strive to make their mark. As you prepare your data, slides, and talking points, there’s a crucial element you can’t overlook—logistics.? Join our virtual event on Thursday, October 17th at 12pm ET to discover how Precision AQ can simplify your experience around #JPMorgan2025. This is your opportunity to partner with a team that makes your conference experience effortless and empowers you to focus on driving your life-changing innovations forward. Click here to register: https://lnkd.in/dSUQgrBP
-
-
Congrats to client City Therapeutics on its launch and $135M Series A financing!
Now entering City limits. Welcome to CityTx! We’re excited to announce our launch today with a vision to build the leading next-generation RNAi therapeutics company, and a $135 million Series A financing led by ARCH Venture Partners. City Therapeutics founders and leadership include many of the creators of the first generation of RNAi therapeutics with the intent of advancing next-generation siRNA-engineering to advance a differentiated pipeline and expand the therapeutic reach of RNAi-based medicines. We plan to make improvements across a range of RNAi trigger molecule design, aspects and maximize our impact on patients with rare and prevalent diseases. There’s a vast opportunity ahead – with better molecules, better delivery and better targets. Learn more: https://lnkd.in/eetrgyaY